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Summary Twelve patients with rectal carcinoma were treated for 2 weeks with the somatostatin analogue
SMS 201.995. Effects of this therapy were assessed using serum marker concentration, Ki67 and gastrin-
immunoreactivity of the primary tumour. In four out of 12 patients, a significant decrease in Ki67 immuno-
reactivity was seen during SMS 201.995 treatment while in the remaining eight patients there was no
significant change in Ki67 expression. Four patients had elevated pretreatment serum carcinoembryonic
antigen (CEA) levels. In two of these four patients, serum CEA levels fell modestly during SMS 201.995
therapy. This is the first clinical evidence that a somatostatin analogue can inhibit the growth of some
colorectal cancers.
Colorectal cancer is the second commonest malignancy in
England and Wales, responsible for 23,500 new cases and
over 17,300 deaths annually. In cases where the tumour is
not cured by surgery or where advanced disease is diagnosed,
the only therapies currently available are radiotherapy and
chemotherapy. Whilst both modalities have achieved real
benefit for patients with colon cancer, their contributions are
modest and should not discourage us from looking for novel
methods of growth control.
Gastrin is an established growth factor for human gastric
and colorectal cancers (Morris et al., 1989; Watson et al.,
1989). The peptide hormone, somatostatin, has been found to
reduce circulating levels of gastrin and reduces the growth of
human colorectal xenografts growing in experimental animals
(Smith et al., 1988). The long acting somatostatin analogue,
SMS 201.995, has also been shown to inhibit the growth of
human gastric cancer xenografts (Watson et al., 1990). In
addition, SMS 201.995 has been shown to reduce serum
concentrations of other potential tumour growth factors such
as insulin-like growth factor (IGF 1) and epidermal growth
factor (EGF) (Ghirlanda et al., 1983; Lambert et al., 1986).
CEA levels are elevated in the serum of a significant
number of patients with advanced colorectal cancer (Roberts
et al., 1988). Changes in sequential serum CEA levels have
been reported to correlate with response to chemotherapy in
patients with metastatic disease (Quentmeir et al., 1989).
Sequential serum CEA levels may therefore be of value in
monitoring response to systemic endocrine therapy such as
the somatostatin analogue SMS 201.995.
The monoclonal antibody Ki67 reacts with a nuclear anti-
gen reported to be present in actively dividing cells (i.e., GI,
S, G2 and M phases of the cell cycle) but not in quiescent
(GO) cells (Gerdes et al., 1984; Gerdes et al., 1984) in breast
cancer Ki67 antigen expression correlates significantly with
histological grade and mitotic index of the primary tumour
(Walker et al., 1988; Bouzubar et al., 1989). Ki67 antigen
expression has also been reported to correlate significantly
with mitotic index in primary colorectal tumours (Shepherd
et al., 1988). Sequential Ki67 measurements of the primary
tumour may therefore be a further method of assessment of
response to endocrine therapy in rectal carcinoma.
The aim of the present study is to evaluate the effect of
subcutaneously administered SMS 201.995 on both the
change in serum tumour marker concentrations and in
tumour kinetics, as assessed by Ki67 immunoreactivity, in
patients with primary rectal carcinoma
Materials and methods
Patient details
From January 1989 to October 1989, 19 patients with histo-
logically confirmed primary rectal adenocarcinoma were con-
sidered suitable for entry into this study. Patients with a
history of myocardial infarction within 6 months prior to the
study, liver or renal failure and any patients who had
received any investigational drug within 4 weeks of entry,
were excluded. Of the 19 eligible patients entered into this
study, 13 were treated with SMS 201.995 (Sandoz), and six
patients were untreated controls. Treatment/control was not
allocated randomly. The controls were patients who did not
wish to be included in the somatostatin study but consented
to the biopsies. This study was approved by the ethical
committee of University Hospital, Nottingham. All patients
gave informed consent and were able to comply with the
study protocol. One insulin-dependent diabetic patient was
withdrawn on the 4th day of SMS 201.995 therapy because
of recurrent hypoglycaemia due to unstable diabetes. Twelve
patients are therefore assessable for response to SMS
201.995.
Treatment schedule
SMS 201.995 was administered subcutaneously for 14 days
by continuous infusion at a dose of 600fg 24 h-' with an
autosyringe and pump. Fasting blood samples were taken
prior to initiation of SMS 201.995 therapy (Day 0), on the
7th day of treatment and at the termination of treatment: full
blood count, urea and electrolytes, liver function tests, blood
sugar, serum gastrin and serum concentration of the tumour
markers CA 19.9 and carcinoembryonic antigen (CEA) were
measured. Measurement of both tumour markers was per-
formed in our own laboratory using the commercially avail-
able CIS radioimmunoassay kits. Serum gastrin was regarded
as elevated if it was above 110 ng 1' (normal range 25-110
ngI`). Similarly, serum CEA and CA 19.9 concentrations
were regarded as elevated if they were above 10 ng ml-' and
33 units ml-' respectively.
Tumour sampling
Multiple rectal tumour biopsies were taken at initiation and
termination of SMS 201.995 therapy from the same areas of
the tumour under direct vision at rigid sigmoidoscopy. The
multiple biopsies of the tumour mass were pooled to yield as
representative a sample as possible. Following 14 days of
SMS 201.995 therapy, the primary tumour was resected at
which time further biopsies of the tumour were taken. In
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control patients, samples were taken at sigmoidoscopy and
then again at the time of resection.
Measurement oftumourproliferation with Ki67 monoclonal
antibody
Tumour biopsy material was disaggregated enzymatically
with collagenase to achieve a single cell suspension (4). The
cell suspension was then fixed (10 min, 1% paraformaldehyde
4°C, followed by 10 min 70% ethanol, at 4°C). One hundred
l of the mouse monoclonal antibody, Ki67 (Dakopatts,
Bucks, UK) at a 1/10 dilution was added to 2 x 105 cells and
incubated for 5 min at 37°C followed by 55 min at room
temperature (22°C). The cells were washed and antibody
binding was detected with an anti-mouse fluoroscein isothio-
cyanate (FITC) conjugate (Dakopatts) used at a 1/80 dilution
(0.5 ml/2 x 105 cells) with an incubation period of 30 min at
room temperature. Cells were analysed on a fluorescence-
activated cell sorter (Armitage et al., 1985) and the mean
linear fluorescence/cell and percentage positive cells/popu-
lation were analysed. Debris and small cells such as RBC and
lymphocytes were gated out of the analysis.
Measurements ofintracellular gastrin immunoreactivity
The single cell suspension from the tumour biopsy specimens
were also analysed for gastrin immunoreactivity by flow
cytometric analysis. One thousand fil of rabbit anti-human
gastrin (G17) antiserum (Dakopatts) at 1/100 dilution (46 ng
protein-' ml-') was added to 2 x 105 cells, and incubated at
room temperature for 60 min. The cells were washed and an
anti-rabbit FITC conjugate (Dakopatts) at 1/80 dilution
(0.5 ml/2 x 105 cells) then added. The degree of gastrin
immunoreactivity was assessed by flow cytometry. Specificity
of anti-gastrin binding was determined by preabsorbing the
antiserum for 3 h at 4°C with 50iLgml-' human G17 (Sigma,
Dorset, UK). Any staining after preabsorption was regarded
as non-specific binding.
Statistical analysis
Pooled tumour tissue was examined in duplicate for both
Ki67 and gastrin immunoreactivity. These data for pretreat-
ment or during treatment were compared by the student
t-test. Triplicate samples of blood were analysed for tumour
markers.
patients, the Ki67 measurements ofthe pre-treatment (Day 0)
biopsies were not significantly different from tumour speci-
mens (Table I). In one patient, the pre-treatment (Day 0)
biopsy gave a lower value for Ki67 staining than the post-
operative tumour specimen (Table I).
In contrast, four of the 12 SMS 201.995 treated patients
(Patients 1, 2, 5 and 6; Table II) had significantly lower Ki67
immunostaining in the post-SMS 201.995 treated (Day 14)
tumour biopsy compared to the pre-treatment (Day 0) biopsy
(Table II) (P<0.05). Ki67 staining remained at this signi-
ficantly lower level post-operatively in one of the four
tumours. In two of the remaining tumours operated on 10
and 23 days after stopping SMS 201.995, there was a signi-
ficant recovery in Ki67 staining of the tumour in material
resected at operation (Table II). The fourth patient with a
significant decrease in Ki67 during therapy did not have a
post-treatment measurement due to an error in tissue hand-
ling.
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Figure 1 a, Serum CEA profile in primary rectal carcinoma
(control group). b, Serum CEA profile in primary rectal car-
cinoma patients treated with SMS 201.995.
Results
Serum markers
Of the six Control patients who did not receive SMS 201.995,
one had an elevated CEA concentration which did not alter
pre-operatively (Figure la).
Of 12 patients who completed the course of SMS 201.995
therapy, four had elevated CEA levels (Figure lb). All four
patients had Dukes C carcinomas. None had liver metastases
either clinically or on intra-operative contact ultrasono-
graphy. In two of these four patients, there was a modest
reduction in serum CEA levels during SMS 201.995 therapy.
In all four patients, post-resection serum CEA levels fell
below pre-operative levels, as would be expected.
Serum CA 19.9 concentrations in Control and SMS
201.995 treated patients were similar both pre- or post-
operatively. Serum gastrin concentration remained within the
normal range in both treated and untreated patients (Figures
2a and b), the normal range of serum gastrin being 25-110
ngl-'.
Ki67 Immunoreactivity
In the six Control patients, tumour biopsies for Ki67
measurements were obtained pre-operatively on Day 0 and
again from the resected tumour specimens. In five of six
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Figure 2 a, Fasting serum gastrin in control group; b, Fasting
serum gastrin profile in SMS 201.995 treatment patients with
primary rectal carcinoma.
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Gastrin immunoreactivity
Anti-gastrin activity was measured in the tumours of only
two Control patients. One patient showed a significant eleva-
tion in the % of tumour cells staining positively in the
post-operative tumour specimen compared to the pre-treat-
ment (Day 0) biopsy (Table III). In the SMS 201.995 group,
two patients, Patients 2 and 6 (Table III), not only had
reduced Ki67 staining post-SMS 201.995 therapy, but also
had significantly reduced anti-gastrin staining. In Patient 2,
there was a 'rebound' in gastrin staining of the post-operative
tumour specimen resected 10 days after cessation of therapy,
which reflected the rebound rise observed in this same patient
with Ki67 staining. Patient 8 (Table II) also has a significant
reduction in anti-gastrin immunoreactivity following SMS
201.995 therapy: Ki67 immunoreactivity was low in both pre-
and post-SMS 201.995 tumour biopsies. In one treated
patient (Patient 2, Table III), the pre-treatment (Day 0)
Table I % Tumour cells (±s.d.) staining positive (+) for Ki67 in
control patients
Pre-treatment biopsy Resected tumour
Patient no. cells s.d. cells s.d.
1 <2 8.4 (0.2)
2 4.1 (0.3) 5.4 (1) NS
3 2.4 (0.1) 6.5 (3) NS
4 12.2 (3) 15.4 (0.5) NS
5 12.2 (5) 12.2
6 3.4 (0.1) 2.1 (1) NS
% ( + ) cells is calculated as mean ofduplicate samples.
biopsy showed significantly lower anti-gastrin staining than
measured in both the post-treatment (Day 0) biopsy and the
post-operative tumour specimens.
Discussion
Hypergastrinaemia has been implicated in the increased
growth of colon cancer in animal models who had proximal
resection of the small bowel (Williamson et al., 1978) and
antral exclusion (McGregor et al., 1982; Besterman et al.,
1982; Elwyn et al., 1985; Sagor et al., 1985). In this study,
SMS 201.995 failed to significantly effect serum gastrin levels
(Figures 2a and b). However, it could still be possible that
SMS 201.995 may affect the local production of gastrin by
the tumour in the same way that it prevents gastrin release
by antral cells (Dembinski et al., 1987), thereby blocking an
autocrine/paracrine growth pathway (Sirinek et al., 1985).
This was addressed in our study by studying intracellular
tumour immunoreactivity to gastrin.
We have previously shown that SMS 201.995 therapy
reduced the growth of a human gastric adenocarcinoma
xenograft grown in nude mice, the cell line used being known
to have high level ofgastrin immunoreactivity (Watson et al.,
1990). In this study, SMS 201.995 reduced gastrin immuno-
reactivity in the primary tumour in three of the 12 SMS
201.995 treated patients: in two of these three patients, a
parallel decrease in Ki67 staining was also noted. However, it
should be noted that in three patients there was an elevation
of intracellular tumour gastrin during therapy (Table II)
which was not associated with any increase in Ki67 immuno-
reactivity (Table II).
Table II % Tumour cells (±s.d.) staining positive ( + ) for Ki67 in SMS 201.995 treated patients
Timefrom
cessation of
Pre-treatment biopsy Post-treatment biopsy Resected tumour treatment to
Patient % (+) % (+) % (+) tumour resection
no. cells s.d. cells s.d. cells s.d. (Days)
1 5.0 (0.4) <2 (0.2)a 12.0 (l)a 10
2 6.5 (0.7) <2 (1)b <2 (0.4)c 13
3 5.5 (0.1) n.d. n.d. 8.0 (0.5) 1
4 5.4 (4) 3.8 (1.6) <2 (0.5) 1
5 8.1 (0.7) <2 (2.6b) n.d. n.d. n.d.
6 7.7 (0.7) <2 (0.5)c 5.9 23
7 4.1 (0.1) n.d. n.d. 4.9 (0.2) 1
8 < 1 (0.3) <2 (0.8) n.d. n.d. 1
9 <2 (0.35) <2 (0.2) n.d. n.d. 7
10 12.4 (0.2) 23 (8.5) 15.3 (1) I
11 <2 (0.5) 4.2 (1) 5.3 (1) 6
12 <2 (0.15) 4.1 (2) 3.1 (2) 6
ap<0.01; bp<0.05; CP< 0.02; When compared to staining achieved with pre-treatment biopsy. n.d. -
not determined. % ( + ) cells is calculated as mean of duplicate samples.
Table III % Tumour cells(±s.d.) stainingpositive ( + ) foranti-G17 immunoreactivity
in control and SMS 201.995 treated patients
Pre-treatment Post-treatment
biopsy biospy Resected tumour
Patient % (+) % (+) % (+)
no. cells s.d. cells s.d. cells s.d.
Control 2 8.3 (0.1) n.d. n.d. 15.4 (I.1)a
Control 6 4.9 (1.4) n.d. n.d. 1.2 (0.5)
SMS treated 1 4.2 (0.9) <2 (0.25)b 22 (7.5)b
SMS treated 2 <2 (0.5) 11 (M)c 9 (0.8)c
SMS treated 4 <2 n.d. n.d. 9.3 (1.2)
SMS treated 5 <2 <2 n.d. n.d.
SMS treated 6 14 (0.3) <2 (0.I)d n.d. n.d.
SMS treated 7 <2 (0.1) n.d. n.d. 6.7 (0.5)
SMS treated 8 69.3 (9.9) 3.8 (0.4)a n.d. n.d.
SMS treated 9 9.5 14 (0.1) n.d. n.d.
SMS treated 11 2 (0.4) 5.7 (2.1) 2.1
SMS treated 12 <2 (0.3) <2 n.d. n.d.
ap<0.01;bp<O.OS;cP<0.002;dP<0.001,when compared to staining achieved with
pre-treatment biopsy. n.d. - not determined. % ( + ) cells is calculated as mean of
duplicate samples.974 S.Y. IFTIKHAR et al.
The most important finding in this study was, however,
that whilst in the Control group, no significant reduction was
observed in Ki67 tumour staining pre-treatment compared to
post-surgery, a significant decrease in Ki67 staining of the
primary tumour was noted in four of the 12 SMS 201.995
-treated patients. Three of these patients who demonstrated
significant inhibition had a further measurement of Ki67 at
resection and two showed a recovery of Ki67 staining in the
resected tumour. The initial reduction in Ki67 on SMS
201.995 therapy followed by a subsequent rise in Ki67 stain-
ing several days after stopping SMS 201.995 supports the
view that these changes in Ki67 expression are due to the
SMS 201.995 therapy. The possibility that SMS 201.995 has
an effect on expression of the Ki67 antigen, but not on the
actual growth of cancer must be considered. We would hope
to address this particular question in a future study by
measuring not only Ki67 staining but also bromodeoxyuri-
dine (BRDU) uptake by the tumour while on SMS 201.995
therapy.
Two out of four (50%) treated patients with raised pre-
treatment (Day 0) serum CEA levels showed a modest fall in
serum CEA concentration during SMS 201.995 therapy. A
fall in serum CEA concentration has previously been report-
ed to correlate with response to chemotherapy in patients
with advanced colorectal cancer. Further studies are required
both to confirm that SMS 201.995 therapy can significantly
lower serum CEA levels and to further correlate these
changes with measurements of tumour kinetics.
Our hypothesis that somatostatin may be more effective in
tumours with an important autocrine growth factor such as
our original work in MKN45G - a human gastric carcinoma
with intracellular gastrin-like growth factor production, is
not well supported by these data. It may well be, however,
that SMS 201.995 exerts its effects via several other growth
factor pathways and also may depend on receptor status.
A previous small study failed to show any objective evi-
dence that the growth ofgastro-intestinal cancer was affected
by the administration of SMS 201.995. However, this may be
dose-related, as the dose administered in the previous study
(Savage et al., 1987) was only 100 yg 24 h-' given as a bolus
compared with the present study in which SMS 201.995 was
infused at a constant rate to deliver 600fg 24 h-'. We
believe that the higher dose of SMS 201.995 administered
subcutaneously as a continuous infusion may offer thera-
peutic potential in the treatment of a subgroup of patients
with colorectal carcinoma and that further studies of SMS
201.995 in patients with colorectal carcinoma are indicated to
confirm this effect and attempt to identify which tumours will
respond.
We are most grateful to Sandoz for providing the SMS 201.995 and
support for this study.
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